1,000 renal transplants at the Massachusetts General Hospital: improved allograft survival for high-risk patients without regard to HLA matching.
Excellent allograft survival is now routinely accomplished following renal transplantation. Changes in immunosuppression have resulted in a significant improvement in early survival for recipients of primary LRD and CD allografts. In our series, crossmatching techniques which accurately assess alloantibody reactivity and not the degree of HLA mismatch have also permitted successful transplantation of such high-risk groups as recipients of second transplants and highly sensitized recipients. However, a yearly attrition rate of allograft loss persists for all recipients. These long-term observations stress the need for newer approaches to immunosuppression in the future, which include protocols that allow for an indefinite tolerance to incompatible donor antigens.
Delmonico
F L
FL
Transplantation Unit, Harvard Medical School, Massachusetts General Hospital, Boston.
Fuller
T C
TC
Cosimi
A B
AB
D000328:Adult; D001900:Boston; D002648:Child; D005500:Follow-Up Studies; D006085:Graft Survival; D006680:HLA Antigens / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016030:Kidney Transplantation / Q000276:immunology*; D012189:Retrospective Studies; D012307:Risk Factors; D014184:Transplantation, Homologous
D006680:HLA Antigens